India's Fertility Tourism, Bioethics Retrospective, and IVI Acquisition

The Times of India reports that Indian couples are traveling abroad and spending crores to pursue sex-selection fertility treatments unavailable domestically. The practice is driven by a strong cultural preference for male children, and the piece documents how families are navigating international fertility markets to access procedures banned in India.

Sex selection is prohibited in many countries but legal in others, and clinics in permissive jurisdictions actively market to international patients. If you are considering fertility treatment abroad, ask your clinic directly which procedures are offered and whether they comply with the laws of both the destination country and your home country. Knowing the legal landscape before you travel protects you.

The Hastings Center for Bioethics has published a piece looking back and ahead at the bioethics of surrogacy. The article appears to be additional coverage of the retrospective first noted in yesterday's brief, with the outlet continuing to surface questions about how the field has evolved and where it is heading.

Worth watching. When a leading bioethics institution publishes a retrospective, it often signals that practitioners and policymakers are revisiting foundational questions. The conversation is worth following as it can shape future regulation.

Vietnam Investment Review has published its own report on IVI Institute's acquisition of The World Egg and Sperm Bank, adding international business press coverage to a deal first reported here on October 16 and confirmed via PR Newswire on October 17. The piece reflects continued global interest in the transaction and its implications for donor access.

This one is getting real traction in international financial media, which suggests the deal is being read as a meaningful consolidation signal across Asian and emerging markets, not just a Western fertility-sector story.

What a Surrogacy Contract Must Cover

A gestational carrier agreement is far more than a formality — it is the legal foundation that protects everyone involved in a surrogacy journey. Before a surrogate ever begins a medical protocol, this contract must be fully signed and, in most cases, court-approved. Understanding what it covers helps both intended parents and surrogates feel grounded and genuinely protected.

The compensation schedule is one of the most detailed sections, outlining the base fee, monthly allowances, and payments tied to specific milestones such as embryo transfer, confirmed heartbeat, and each trimester. Equally important are the clauses governing medical decision rights — specifically, who has authority over medical choices during the pregnancy and how those decisions are communicated. Selective reduction and termination clauses must be addressed directly and honestly, as these are among the most sensitive topics in any surrogacy agreement, and both parties must be fully aligned before signing.

The multiples policy clarifies how the parties approach a pregnancy with more than one fetus, including any agreed limits on how many embryos are transferred. Contact and communication expectations set the tone for the entire relationship — how often updates are shared, whether the intended parents attend appointments, and how the parties stay connected after birth. Life insurance requirements ensure that the surrogate carries adequate coverage throughout the pregnancy, a non-negotiable protection for her family.

The contract also addresses what happens in the event of miscarriage, medical complications, or circumstances that affect the surrogate's health and ability to continue. These provisions bring clarity during moments that are already emotionally difficult.

Perhaps most importantly, both the surrogate and the intended parents must each have their own independent attorney review and negotiate the agreement on their behalf — because no single attorney can ethically represent both sides of the same contract.